Development of small molecule Limk inhibitors for probing ocular diseases

开发用于探测眼部疾病的小分子 Limk 抑制剂

• 批准号: 8306733
• 负责人: Yangbo Feng
• 金额: $ 29.7万
• 依托单位: SCRIPPS FLORIDA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8306733
• 关键词: Actin-Binding Protein; Actins; Adverse effects; Alzheimer' s Disease; Benzimidazoles; Biochemical; Biological Assay; Biological Process; Biology; Brain; Cells; Central Nervous System Diseases; Development; Disease; Evaluation; Eye; Glaucoma; Goals; Inflammation; Inhibitory Concentration 50; Intracranial Aneurysm; Malignant Neoplasms; Microtubules; Molecular; Molecular Probes; Neuraxis; Pathway interactions; Peer Review; Penetration; Pharmaceutical Preparations; Phosphorylation; Phosphotransferases; Physiologic Intraocular Pressure; Property; Protein Isoforms; Protein-Serine-Threonine Kinases; Public Health; Publications; Reporting; Research; Rho-associated kinase; Screening procedure; Signal Transduction; Solubility; Williams Syndrome; actin depolymerizing factor; base; benzimidazole; cofilin; design; drug discovery; inhibitor/antagonist; kinase inhibitor; novel; polymerization; primary pulmonary hypertension; scaffold; small molecule; therapy development; tool

DESCRIPTION (provided by applicant): Lim kinases (Limk) are serine/threonine kinases which regulate microtubule stability and actin polymerization by phosphorylation and inactivation of actin binding proteins, the actin depolymerizing factor (ADF) and cofilin. The abnormal expression of either Limk isoform, Limk1 or Limk2, is implicated in numerous malfunctions that are related to a variety of diseases, such as glaucoma, ocular inflammation, cancer, primary pulmonary hypertension, intracranial aneurysms, Alzheimer's disease, and Williams syndrome. Lim kinases are downstream effectors of Rho kinases (ROCK). ROCK inhibitors have been demonstrated to be effective in reducing intraocular pressure (IOP) in recent years, and it is believed that this effect of ROCK inhibitors is through the Limk pathway. Unlike Rho kinases which have multiple substrates, Lim kinases serve as points of signal integration and channel this information to a select few substrates, which makes Lim kinases good targets for drug discovery with much less potential side effects. Despite the attractive potential of Limk inhibitors, there have been no small molecule inhibitors reported in peer-reviewed publications which showed simultaneously good potency, high selectivity, good solubility and appropriate DMPK properties for ocular and/or other CNS applications (such as good eye and/or brain penetration properties). In this application, we propose to develop novel small molecule Limk inhibitors based on a benzimidazole scaffold. Through the synthesis and evaluation of approximately 100 compounds total in two years, we anticipate discovering Limk inhibitors with biochemical IC50 values of < 20 nM, cell-based IC50 values of < 200 nM, good selectivity, excellent solubility, and with good eye and/or brain penetration properties. These compounds will serve as useful molecular tools to study the biological functions of Limk, and to probe ocular diseases and other Limk related CNS diseases. )

描述(申请人提供)：LIM激酶(LIMK)是一种丝氨酸/苏氨酸激酶，通过肌动蛋白结合蛋白、肌动蛋白解聚因子(ADF)和粘连蛋白的磷酸化和失活来调节微管的稳定性和肌动蛋白聚合。LIMK亚型LIMK1或LIMK2的异常表达与多种疾病有关，如青光眼、眼部炎症、癌症、原发性肺动脉高压、颅内动脉瘤、阿尔茨海默病和威廉姆斯综合征。LIM激酶是Rho激酶(ROCK)的下游效应器。近年来，ROCK抑制剂已被证明具有有效的降眼压作用，并被认为是通过LIMK途径发挥作用的。与具有多个底物的Rho激酶不同，LIM激酶作为信号集成点，将信息传递到选定的几个底物，这使得LIM激酶成为药物开发的良好靶点，潜在的副作用要小得多。尽管LIMK抑制剂具有诱人的潜力，但在同行评议的出版物中，没有报道小分子抑制剂同时具有良好的效力、高选择性、良好的溶解性和适当的DMPK特性，用于眼科和/或其他中枢神经系统应用(如良好的眼睛和/或脑穿透特性)。在这一应用中，我们建议开发基于苯并咪唑支架的新型小分子LIMK抑制剂。通过在两年内合成和评估大约100种化合物，我们预计将发现生化IC50值为~lt；20 NM、细胞IC50值为~lt；200 NM、选择性好、溶解性好、具有良好的眼和/或脑渗透性能的LIMK抑制剂。这些化合物将成为研究LIMK生物学功能、探索眼部疾病和其他LIMK相关中枢神经系统疾病的有用分子工具。)